Target intelligence / Profile preview

D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan precursors (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall component, Peptidoglycan precursor
01

Overview

The D-alanyl-D-alanine (D-Ala-D-Ala) terminus is a critical structural motif found on the pentapeptide side chains of peptidoglycan precursors, such as Lipid II, in Gram-positive bacteria like Streptococcus pneumoniae (StatPearls, 2023). This dipeptide serves as the essential substrate for transpeptidase enzymes, also known as penicillin-binding proteins, which catalyze the cross-linking of peptidoglycan layers to maintain the structural integrity of the bacterial cell wall (Nature Reviews Microbiology, 2006). Glycopeptide antibiotics, including vancomycin and teicoplanin, exert their bactericidal effect by binding with high affinity to the D-Ala-D-Ala terminus through a network of five hydrogen bonds (PubMed, PMID: 16921300). This interaction creates a steric cap that blocks the enzymes responsible for polymerizing and cross-linking the cell wall, leading to osmotic instability and cell death (Journal of Biological Chemistry, 2008). Because this target is located on the exterior of the cytoplasmic membrane, it is highly accessible to drugs, though therapeutic challenges include the emergence of resistance through the modification of the terminus to D-alanyl-D-lactate (StatPearls, 2023).

Other names
D-alanyl-D-alanineD-Ala-D-Ala dipeptidePeptidoglycan pentapeptide terminusLipid II C-terminus
02

Mechanism of action

Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus of peptidoglycan precursors via hydrogen bonding, sterically hindering the transglycosylation and transpeptidation reactions required for cell wall assembly.

03

Biological functions

Cell wall synthesisPeptidoglycan cross-linkingStructural integrity
04

Disease associations

InfectionPneumoniaMeningitisBacteremia
05

Safety considerations

NephrotoxicityOtotoxicityRed man syndromeDevelopment of resistance (D-Ala-D-Lac substitution)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

Minimum Inhibitory Concentration (MIC)vanA/vanB gene presence

Beyond the preview

Go deeper on D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan precursors (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan precursors (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call